WMSA
ATXS

Weiss Multi-Strategy Advisers’s Astria Therapeutics ATXS Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-80,000
Closed -$614K – 39
2023
Q4 		$614K Buy
80,000
+29,461
+58% +$163K 0.01% 468
2023
Q3 		$377K Sell
50,539
-173,706
-77% -$1.48M 0.01% 494
2023
Q2 		$1.87M Buy
224,245
+17,857
+9% +$206K 0.04% 479
2023
Q1 		$2.75M Buy
206,388
+141,820
+220% +$1.92M 0.06% 368
2022
Q4 		$961K Buy
+64,568
New +$666K 0.03% 466

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ATXS Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 80,000 shares — an estimated $614K sold.

Weiss Multi-Strategy Advisers first reported a position in ATXS in Q4 2022 and held it in 5 quarters. The position peaked at $2.75M in Q1 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 80,000 Astria Therapeutics shares in Q1 2024, an estimated $614K.
  • Weiss Multi-Strategy Advisers first reported a position in Astria Therapeutics in Q4 2022 and held it in 5 quarters.
  • Weiss Multi-Strategy Advisers's Astria Therapeutics position peaked at $2.75M in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.